These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34131916)

  • 1. Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020).
    Merino-Gutierrez V; Borrego JF; Puig J; Hernández A; Clemente-Vicario F
    J Small Anim Pract; 2021 Oct; 62(10):881-885. PubMed ID: 34131916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
    Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
    Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
    London C; Mathie T; Stingle N; Clifford C; Haney S; Klein MK; Beaver L; Vickery K; Vail DM; Hershey B; Ettinger S; Vaughan A; Alvarez F; Hillman L; Kiselow M; Thamm D; Higginbotham ML; Gauthier M; Krick E; Phillips B; Ladue T; Jones P; Bryan J; Gill V; Novasad A; Fulton L; Carreras J; McNeill C; Henry C; Gillings S
    Vet Comp Oncol; 2012 Sep; 10(3):194-205. PubMed ID: 22236194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
    Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
    Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
    Hicks KA; Leeper HJ; Curran KM
    Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
    Musser ML; Johannes CM
    BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
    Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
    Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia.
    Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD
    N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma.
    Hocker SE; Higginbotham ML; Schermerhorn T; Henningson J
    Res Vet Sci; 2017 Dec; 115():484-489. PubMed ID: 28783596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
    Gustafson TL; Biller B
    J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
    Harper A; Blackwood L
    J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
    Elliott JW
    J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
    Kim C; Matsuyama A; Mutsaers AJ; Woods JP
    Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
    Piscoya SL; Hume KR; Balkman CE
    Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review.
    Frezoulis P; Harper A
    Vet Comp Oncol; 2022 Jun; 20(2):362-371. PubMed ID: 34981886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
    Musser ML; Taikowski KL; Johannes CM; Bergman PJ
    BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.